Patient Guide: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 237 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06208150
Status: 🟢 Enrolling Now
Condition: Multiple Myeloma, Neoplasms, Plasma Cell
Phase: PHASE3

Where You Can Participate

This study is available at 237 locations across the country.

Top locations include:
  • • Clovis, California
  • • Santa Monica, California
  • • New Haven, Connecticut
  • • And 234 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide - Join Clinical Trial NCTNCT06208150

How to Join This Clinical Trial - NCTNCT06208150

Learn how to participate in this PHASE3 trial studying an investigational therapy for Multiple Myeloma, Neoplasms, Plasma Cell. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Myeloma, Neoplasms, Plasma Cell. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Myeloma, Neoplasms, Plasma Cell
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06208150 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 237 locations. Find a study site near you:

Clinical Research Site

Clovis, California 93611 - United States

Status: RECRUITING

Clinical Research Site

Santa Monica, California 90404 - United States

Status: RECRUITING

Clinical Research Site

New Haven, Connecticut 06519 - United States

Status: RECRUITING

Clinical Research Site

Newark, Delaware 19713 - United States

Status: RECRUITING

Clinical Research Site

Hollywood, Florida 33021 - United States

Status: RECRUITING

Clinical Research Site

Tampa, Florida 33612 - United States

Status: RECRUITING

Clinical Research Site

Atlanta, Georgia 30322 - United States

Status: RECRUITING

Clinical Research Site

Coeur d'Alene, Idaho 83814 - United States

Status: COMPLETED

Clinical Research Site

Waukee, Iowa 50263 - United States

Status: RECRUITING

Clinical Research Site

Louisville, Kentucky 40207 - United States

Status: RECRUITING

And 227 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Multiple Myeloma, Neoplasms, Plasma Cell:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships